Document Detail

Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.
MedLine Citation:
PMID:  20953817     Owner:  NLM     Status:  In-Data-Review    
We sought to evaluate the association between C-reactive protein (CRP) sampled on admission and short- and long-term mortality in patients with acute coronary syndromes (ACS) undergoing early invasive treatment. Baseline levels of CRP were determined in 2,974 patients with moderate and high-risk ACS undergoing an early invasive treatment strategy in the large-scale randomized ACUITY trial. The relationship of CRP to 30-day and 1-year clinical outcomes were assessed according to quartiles of CRP values. Patients with CRP levels in the fourth quartile compared to the first quartile had significantly higher 30-day mortality (2.3 vs. 0.3%, P = 0.0004) and 1-year mortality (5.5 vs. 2.8%, P = 0.0003). CRP level as a continuous variable was associated with 30-day mortality (OR [95% CI] for one unit increase in logarithmically transformed CRP level = 1.42 [1.08-1.89], P = 0.01) and 1-year mortality (OR [95% CI] = 1.24, [1.04-1.47], P = 0.02). By multivariable analysis, higher baseline CRP levels independently predicted 30-day and 1-year mortality, a relationship that was particularly strong for patients with the highest quartile of CRP (OR [95% CI] = 5.19 [1.14-23.68], P = 0.009). In troponin-positive patients, increasing quartiles of CRP were associated with a trend for 30-day mortality (P (trend) = 0.08) and a significant increase in 1-year mortality (P (trend) = 0.02); this relationship was not present in troponin-negative patients. Baseline CRP level is a powerful independent predictor of both early and late mortality in patients with ACS being treated with an early invasive strategy, especially in troponin positive patients.
Adriano Caixeta; Gregg W Stone; Roxana Mehran; Edwin A Lee; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; E Magnus Ohman; Tullio Palmerini; George Syros; Christos Kittas; Martin Fahy; W Craig Hooper; Alexandra J Lansky; George D Dangas
Related Documents :
10824887 - Role of serum c-reactive protein as a marker of hepatocellular carcinoma in patients wi...
21204907 - Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients p...
15280837 - Pilot study of etanercept in patients with relapsed cutaneous t-cell lymphomas.
17111427 - Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squ...
21596367 - Harmful effects of nsaids among patients with hypertension and coronary artery disease.
16216027 - Heart block and empirical therapy after transcatheter closure of perimembranous ventric...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  31     ISSN:  1573-742X     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  154-64     Citation Subset:  IM    
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
Next Document:  Interleukin-10 -1082 promoter polymorphism and gastric cancer risk in a Chinese Han population.